Alexion Pharmaceuticals ( ALXN ) a biopharmaceutical company which markets the blockbuster drug Soliris, is near the end of its journey to develop an even better version of Soliris called ALXN1210. Both Soliris (eculizumab) and ALXN1210 are antibodies which bind the complement protein C5, whic…

Background of the Company Achillion ( ACHN ) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. The complement system is a part of the human innate immune system and is believed to comprise three pathways - the alt…

The approval of any drug by the FDA is based on the concept of benefit/risk. Obviously, for a drug to get approved, those knowledgeable in the field must believe that the benefits of the drug outweigh the risks. This benefit/risk ratio is a moving target. The risk that a patient would find acc…

Today's public figures can no longer write their own speeches or books, and there is some evidence that they can't read them either . - Gore Vidal The biotech sector had a decent performance in the previous week as the overall market drifted up powered by strong economic reading…